



DISCLAIMER

This presentation has been prepared by Hyphens Pharma International Limited (the "**Company**") and, together with its subsidiaries, the "**Group**").

This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated, photographed or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated or quoted, directly or indirectly, to any person either in your organisation or elsewhere.

None of the Company, DBS Bank Ltd. (the "**Sponsor**") nor any of their respective affiliates, advisors and representatives makes any representation regarding, or assumes any responsibility or liability whatsoever (in negligence or otherwise) for, the accuracy or completeness of, or any errors or omissions in, any information contained herein nor for any loss howsoever arising from any use of the content in this presentation.

By attending or viewing all or part of this presentation, you:

- represent and warrant that you are lawfully able to receive this presentation under the laws of the jurisdiction in which you are located and all other applicable laws;
- agree to be bound by the limitations and restrictions described herein; and
- agree to maintain confidentiality regarding the information disclosed in this presentation and to continue to adhere to all applicable securities and insider trading rules and laws in any jurisdiction at all times.

This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in Singapore or any other jurisdiction nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever.

The information in this presentation is a summary only and does not purport to contain all of the information that may be required to evaluate the Company or any potential transaction. Any potential transaction could be made available to you in accordance with applicable laws and regulations, including the distribution of any required documents for such potential transaction and such documents will supersede all prior information provided to you, herein or otherwise. Information in this presentation is qualified in its entirety by reference to an offering document for any potential transaction, if it proceeds.

None of the Company, the Sponsor, and any of their respective holding companies, subsidiaries, associated undertakings, controlling persons, affiliates, and any of their respective directors, officers, partners, employees, agents, advisers or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation. It is not the intention to provide, and you may not rely on the content of this presentation as providing, a complete or comprehensive analysis of the Company's or the Group's financial or trading position or prospects. The information and opinions contained in this presentation is provided as at the date hereof (unless otherwise indicated) and are subject to change without notice. This presentation may not contain all material information concerning the Company or the Group.

The information contained in this presentation has not been independently verified. The accuracy and completeness of the information and opinions in this presentation is not guaranteed and no representation or warranty, expressed or implied, is made as to, and no reliance, in whole or in part, should be placed on the fairness, accuracy, completeness or correctness of the information, opinions or assumptions contained herein. Further, nothing in this presentation should be construed as constituting legal, business, tax or financial advice. None of the Sponsor and its subsidiaries or affiliates has independently verified, approved or endorsed the material herein.


The information in this presentation includes historical information about and relevant to the Group that should not be regarded as an indication of the future performance of the Group or the value of the shares of the Company. This presentation also contains forward-looking statements that may be identified by their use of words like "plans", "expects", "will", "anticipates", "believes", "intends", "depends", "projects", "estimates" or other words of similar meaning and that involve assumptions, risks and uncertainties. All statements that address expectations or projections about the future and all statements other than statements of historical facts included in this presentation, including, but not limited to, statements about the strategy for growth, product development, market position, expenditures, and financial results, are forward-looking statements. Such forward-looking statements are based on certain assumptions and expectations of future events regarding the Group's present and future business strategies and the environment in which the Group will operate, and must be read together with those assumptions. No assurance or guarantee is given that these assumptions and expectations are accurate or will be realised. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. These risks, uncertainties and assumptions include, without limitation, general industry and economic conditions, interest rate trends, cost of capital and capital availability, competition from other entities, shifts in customer demand, customers and partners, changes in operating expenses including employee wages, benefits and training, governmental and public policy changes and the continued availability of financing in the amounts and the terms necessary to support future business. Predictions, projections or forecasts of the economy or economic trends of the markets are not necessarily indicative of the future or likely performance of the Group. Past performance is not necessarily indicative of future performance. You are cautioned not to place undue reliance on these forward-looking statements, which are based on the Company's current view of future events. None of the Company and the Sponsor, their respective affiliates and their respective agents assumes any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise.

Neither this presentation nor any of its content may be used without the prior written consent of the Company and the Sponsor. Any forwarding, distribution or reproduction of the information in this presentation electronically or otherwise, in whole or in part, is unauthorised.



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group





RECAP FY2019

2. Strengthened human talent

New Independent Director



New Management Team



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



RECAP FY2019

3. Expanded & enhanced product offerings




Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



RECAP FY2019

4. Analyst initiated coverage @ Target price: S\$0.25 – S\$0.285



INVESTMENT BANKING
Top Singapore Small Cap Companies

20 Jewels 2019 Edition

Together We Progress

RHB

Singapore Initiating Coverage

3 July 2019

Hyphens Pharma (HYP SP)

Undervalued And Under-Covered; Initiate **BUY**

Healthcare | Pharmaceuticals

Buy

Target Price (Return)	S\$0.25 (+28%)
Price	S\$0.196
Market Cap	US\$43.5m
Avg Daily Turnover (USD\$000,000)	26/35

Hyphens Pharma Intl Ltd
Leveraging on trust with doctors for profitability

SINGAPORE | HEALTHCARE | UPDATE

- Specialty pharmaceuticals the major earnings driver, rising from 52% of total revenue in FY18 to 57% in FY19.
- High product barriers, brand reputation and product efficacy will enable Hyphens to maintain its premium.
- Revenue generated in emerging countries.
- The stock trades at decent dividend yield.

Company Background
Hyphens Pharma, an pharmaceutical and consumer healthcare group, has a direct presence in Indonesia and the Philippines, covering five additional Asian countries market.

Hyphens Pharma International Limited
Target price: **S\$0.285 (+46%)**

BUY
Price: **S\$0.196** (as at 16 November 2019)

Healthy prospects in ASEAN
Hyphens Pharma International Limited (Hyphens Pharma, Company or the Group) is a leading specialty pharmaceutical and consumer healthcare group with a diverse geographical footprint. The Group develops and markets proprietary dermatological and healthcare supplements, distributes pharmaceuticals and medical supplies in Singapore and markets and sells specialty pharmaceutical products in the burgeoning ASEAN region.

Complex local drug regulatory framework and long lead time to gain acceptance are key barriers to entry. Hyphens has a 20-year track record in building up a distribution network in ASEAN. Each country has its unique regulatory requirements to accept and approve the sale and consumption of drugs. The process entails specialist knowledge in medical and healthcare practices, and continuous engagements with medical practitioners to gain their acceptance of the products.





Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



RECAP FY2019


5. Investor outreach





Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group





INVESTING FOR GROWTH

1

Establishing a broader geographical footprint

- Cementing leadership position in Singapore and deepening presence in ASEAN
- Expanding international footprint in Asia, Middle East and Africa

2

Investment in proprietary brands

- Driving growth of skin health portfolio through Ceradan® and TDF® brands
- Nurturing Ocean Health® as a leading nutritional supplement brand of Singapore
- R&D for new products, improve formulation & generate scientific validation



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



INVESTING FOR GROWTH

3

Strengthening specialty pharma portfolio

- Launching new specialty pharma products in regional markets
- Seeking licensing opportunities for new products

4

Reinforcing medical hypermart and digital segment

- Continue to leverage its broad network in the Singapore market
- Exploring new digital business initiatives

5


Acquisitions

- Continue to source for synergistic opportunities




Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group





1.1 QUARTERLY REVENUE RISING

S\$'000





Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group




1.2 SEGMENT REVENUE

Business Segments




Geography

FY2019




FY2018



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



2 IMPROVING MARGINS



3 STRONG FINANCIAL POSITION & CASH FLOW

S\$'000	31 Dec 2019	31 Dec 2018
Total assets	80,131	74,979
Cash & cash equivalents	26,165	22,353
Total liabilities	36,055	35,817
Financial liabilities	300	3,000
Total equity	44,076	39,162
NAV per share (cents)	14.67	13.05

S\$'000	FY2019	FY2018
Cashflow from operating activities	9,454	7,536
Cashflow used in investing activities	(450)	(3,324)
Cashflow used in financing activities	(5,192)	5,848
Net cash inflow	3,812	10,060
Free cash flow*	8,970	4,128

* Net Cash From Operations + Interest/Dividends Received - Net Interest Paid - Capex

4 HIGHER DIVIDENDS

S\$'000	Dividend	Yield ^(a)	Div / NP ^(b)
FY2019	1 cent	4.4%	46.0%
FY2018	0.55 cents	2.4%	30.5%

(a) Yield is computed based on total dividends declared for the financial year divided by closing price of S\$0.255 @ 28 Feb 2020.

(b) At least 30% of Net Profits Attributable to Shareholders in FY2018 & FY2019 intended to be distributed as dividends.

Total Shareholder Return

Period	Capital Appreciation	Dividend Received	Total Shareholder Return
3 Months	-	-	- %
6 Months	+0.025	-	+12.50 %
1 Year	+0.031	0.006	+19.07 %


Source: Investor-One



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



5 MANAGEMENT OWNERSHIP



¹ Owned by Mr. Lim See Wah, CEO and Dr. Tan Kia King, Non-Executive Director

² Mr. Tan Chwee Choon, Executive Director

³ As at 12 Mar 2019



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



Q&A



Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group



Hyphens

Hyphens Pharma International Limited (SGX: 1J5)
 16 Tai Seng Street, Level 4, Singapore 534138
www.hyphensgroup.com

[in](#) Follow us on LinkedIn